Key Highlights

● Sanofi ADRs were indicated at $44.82, up 3.92%, as of 8:23 a.m. ET.

● Paris shares gained 5.4% after third-quarter results beat estimates and the outlook was raised.

● Global Dupixent sales reached $6.5 billion in the quarter, up 35%.

● Vaccine sales fell 6.6%, and the company signaled interest in larger acquisitions.

Sanofi (NASDAQ:SNY) American depositary shares were rising before Friday's US open. A pre-market table showed them at $44.82, up 3.92%, in a snapshot updated at 8:23 a.m. ET.

The move tracks a rally in Paris. Market reports said Sanofi shares gained 5.4% after the French drugmaker posted third-quarter results ahead of analyst expectations and raised its outlook. Sanofi was among the strongest large-cap gainers in a Stoxx 600 that was otherwise slightly lower.

Dupixent is the engine

The key driver is Dupixent, the antibody treatment for eczema, asthma, COPD and other inflammatory conditions that Sanofi co-developed with Regeneron (NASDAQ:REGN). Regeneron, which also reported on Friday, said in its SEC filing that global Dupixent sales recorded by Sanofi reached $6.5 billion in the quarter, up 35%. The automated summary cites Dupixent growth of 34.8%.

Regeneron CEO Leonard Schleifer called it "an outstanding quarter for Regeneron, with Dupixent, EYLEA HD, and Libtayo each achieving record net sales." Regeneron's shares were up 6.87% in the 8:23 a.m. snapshot, helped by the same drug.

The automated summary also says Sanofi raised its 2026 guidance, signaled interest in larger acquisitions, and reported a 6.6% decline in Vaccine sales. Those details come from an automatically generated note and could not be checked against Sanofi's release in the sources reviewed, so the exact guidance range is not given here.

The Partnership structure explains why one drug moves two stocks. Sanofi books Dupixent's global net sales, while Regeneron shares in the collaboration's profits. Strong Dupixent Demand therefore shows up in Sanofi's Revenue line and in Regeneron's collaboration income, which is why both companies' shares are rising on Friday.

The vaccines dip is worth noting. Sanofi is one of the world's largest vaccine makers, and that Business has faced softer demand and pricing. The company is still investing in it. Novavax (NASDAQ:NVAX) said this week it earned a $125 million milestone payment after Sanofi launched a Phase 3 trial in Europe of a combined flu and COVID-19 vaccine, according to market data.

Index and market backdrop

Sanofi's ADRs trade on Nasdaq and are part of the Nasdaq Composite, which includes foreign companies' depositary shares listed on the exchange. That puts Sanofi among the few Nasdaq Composite constituents rising on a morning when the index's big tech names are under pressure.

Market quotes at about 8 a.m. ET showed Nasdaq-100 futures down 2.6% and S&P 500 futures down 1.1%, after results from Amazon (NASDAQ:AMZN) and Intel (NASDAQ:INTC) revived worries about AI spending. Dow futures were flat as money rotated into health care and energy. Other drugmakers were higher in the snapshot, including GSK (NYSE:GSK), up 2.71%, Gilead Sciences (NASDAQ:GILD), up 5.30%, and Eli Lilly (NYSE:LLY), up 2.78%.

The gap between the Paris gain and the smaller pre-market rise in New York may partly reflect the weaker US tape, though ADR prices often catch up with the home market once regular trading begins. Health care is among the sectors on track for solid October gains, according to market reports.

A signal of interest in bigger deals, if confirmed, would be a double-edged sword. Acquisitions could add growth beyond Dupixent, but large deals bring integration risk and could limit share buybacks.

Risks and what to watch

Sanofi relies heavily on Dupixent, so any safety issue, competitive launch, or pricing pressure on that drug would hit the stock hard. US drug-pricing policy and pharmaceutical tariffs, set at up to 100% with deal rates of 15% under Section 232, remain sources of uncertainty for European drugmakers.

After the 9:30 a.m. ET open, watch whether Sanofi's ADRs close the gap with the larger gain in Paris. Watch also for analyst estimate changes and for any comments from management on Acquisition targets. Next week's US midterm elections on Tuesday could shape the outlook for drug-pricing policy.